Valuation: Pacific Software, Inc.

Market Cap 48.82M 42.44M 39.5M 36.27M 68.49M 4.66B 69.55M 466M 183M 2.32B 183M 179M 7.78B P/E 2019
-2.65x
P/E 2020 -41.2x
Enterprise Value 49.19M 42.76M 39.8M 36.54M 69.01M 4.7B 70.08M 469M 184M 2.34B 185M 181M 7.84B EV / Sales 2019
-
EV / Sales 2020 2,435,972,350x
Free-Float
99%
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2026-06-09
Director TitleAgeSince
Chairman 74 2016-10-21
Change 5-day change 1-year change 3-year change Capi.($)
-22.83%-.--% - - 3.12M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+36.40%+125.75% 16.11B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -3.63%+1.05%+62.16%+89.14% 27.82B
Weighted average by Cap. -1.60%+2.03%+79.78%+108.61%

Financials

2019 2020
Net sales - 0.02 0.02 0.02 0.01 0.03 1.91 0.03 0.19 0.07 0.95 0.08 0.07 3.19
Net income -21.11M -18.35M -17.08M -15.68M -29.62M -2.02B -30.08M -201M -79.03M -1B -79.29M -77.55M -3.36B -1.17M -1.02M -950K -872K -1.65M -112M -1.67M -11.2M -4.4M -55.81M -4.41M -4.31M -187M
Net Debt -101K -87.41K -81.36K -74.7K -141K -9.6M -143K -959K -376K -4.78M -378K -369K -16.02M 367K 319K 297K 273K 515K 35.08M 523K 3.5M 1.38M 17.46M 1.38M 1.35M 58.56M
Logo Pacific Software, Inc.
PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.
Employees
-